About Quanterix
Quanterix focuses on ultra-sensitive biomarker detection for early disease detection and monitoring in biotechnology and healthcare. Their main technology, Simoa (Single Molecule Array), allows for the identification of biomarkers at very low levels, which is crucial for detecting diseases before symptoms appear. Quanterix differentiates itself by enhancing the sensitivity and specificity of biomarker detection, serving clients like pharmaceutical companies and clinical labs. The company's goal is to empower early disease detection and monitoring to improve patient outcomes.
Lexington, KentuckyHeadquarters
2007Year Founded
$118.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Risks
Securities fraud investigations could lead to legal liabilities and reputational damage.
Restatement of financial statements may undermine investor confidence and affect stock performance.
Integration challenges with Akoya Biosciences may impact operational efficiency and strategic goals.
Differentiation
Quanterix's Simoa technology offers ultra-sensitive biomarker detection, crucial for early disease identification.
The company's platform allows rapid quantification of proteins in complex biological samples.
Quanterix's focus on single-molecule analysis sets it apart in clinical diagnostics.
Upsides
Acquisition of EMISSION enhances Simoa platform, boosting multi-plex capabilities and OEM targeting.
Integration with Akoya Biosciences could expand tissue-based biomarker detection market opportunities.
Participation in J.P. Morgan Healthcare Conference may attract new investors and partners.
Funding
Total raised$118.67 M
Latest valuation$42.50 M
StageIPO
POST IPO EQUITY
1/31/2021$288
SERIES D
7/31/2017$8
$42.50 MGRANT
12/31/2013N/A
$18
$92.50 MSERIES B
7/31/2011$6
$30.00 MEARLY VC
9/30/2010$2
$12.50 MSERIES A
7/31/2008$15
$75.00 M